Bilibili Inc

Bilibili provided an update on its two-year, $300 million share repurchase program initiated earlier in June 2026. As of June 30, the company had repurchased 1.9 million of its listed securities for a total cost of approximately $31.3 million under this program. For the first six months of 2026, total repurchases reached 4.8 million securities at a cost of about $100.1 million. The activity reflects ongoing capital structure management and a commitment to shareholder value.

Absci shares surged 24% in premarket trading after the biotechnology company reported positive interim Phase 1 safety data for its hair-loss antibody treatment ABS-201, while FuelCell Energy jumped 16% on a strategic agreement to supply up to 380 megawatts of clean power for data centers. Cerebras Systems tumbled about 14% after forecasting 2026 adjusted gross margins of 38% to 41%, below the 47% margin reported in the first quarter, in its first earnings report since its IPO. FedEx fell 7.3% after issuing a fiscal 2027 earnings outlook that missed Wall Street expectations, despite reporting fourth-quarter earnings and revenue above estimates. Bilibili rose 2.4% after unveiling a new $300 million share repurchase program that will remain in place for 24 months.

Bilibili's board of directors has authorized a new share repurchase program of up to $300 million. The program covers the company's Class Z ordinary shares and American depositary shares over the next 24 months, effective June 24, 2026. Bilibili intends to fund the repurchases from its existing cash balance. The board will review the program periodically and may adjust its terms and size.